Physician profile
Mark K Walsh
NPI 1003952318
$6,266.10
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $340 · 2021: $82.24 · 2022: $862 · 2023: $1,480 · 2024: $956 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,273.43 | 2019-2025 | Constellation, Ngenuity |
| Novartis Pharmaceuticals Corporation | $814.87 | 2019-2020 | |
| Alimera Sciences, INC. | $524.77 | 2020-2024 | Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $459.62 | 2019-2025 | Eylea Hd |
| Genentech USA, INC. | $421.93 | 2019-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $355.91 | 2023-2025 | Syfovre |
| Abbvie INC. | $300.95 | 2022-2025 | Durysta |
| Aerie Pharmaceuticals, INC. | $260.55 | 2019 | |
| Mallinckrodt Hospital Products INC. | $145.81 | 2025 | Acthar |
| Glaukos Corporation | $130.00 | 2020 | |
| Kala Pharmaceuticals, INC. | $124.98 | 2019 | |
| Genentech, INC. | $106.66 | 2023-2024 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $83.27 | 2024-2025 | Izervay |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Bausch & Lomb Americas INC. | $47.16 | 2023-2025 | Xipere, Retisert, Visudyne |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Coherus Oncology, INC. | $30.11 | 2023 | |
| Harrow Eye, LLC | $27.83 | 2025 | Triesence |
| Spark Therapeutics, INC. | $20.22 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.61 | 2025 | Yutiq |
| Allergan, INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.